Cargando…
Dyshidrotic eczema in two patients on secukinumab for plaque psoriasis: A case report
Secukinumab was the first fully human anti-interleukin-17a monoclonal antibody and successfully treated moderate-severe psoriasis. These new, targeted, medications are becoming more ubiquitous, but long-term side effects are not fully known. Post-market surveillance is crucial to identify delayed ad...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
SAGE Publications
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7011358/ https://www.ncbi.nlm.nih.gov/pubmed/32095241 http://dx.doi.org/10.1177/2050313X20904561 |